Chief Financial Officer · KalVista Pharmaceuticals, Inc. · Common Stock
Side
SELL
Value
$38K
Shares
1,862
Price
$20.22
Executed
Apr 17, 2026
Disclosed
Apr 20, 2026
Disclosure timeline3 days from execution to publication · legal deadline 2 business days
Apr 17 executedApr 20, 2026 disclosed
KALV · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 1 business day after execution (deadline: 2)
Historical behavior+4 / 15
1 prior trade recorded in this security
Frequency & clustering+10 / 15
2 other actors traded the same direction within 14 days
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Piekos Brian filed this Form 4 reporting a open-market sale of KALV on Apr 17, 2026. It became public on Apr 20, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Financial Officer
Piekos Briancik:0001815308
Issuer
KalVista Pharmaceuticals, Inc.cik:0001348911
Revision history · 0
No field has changed since this record was first ingested.
